8月5日，康西哥盘中上涨5.06%，报67.31美元/股，成交额1.48亿美元。
消息面上，Bernstein于8月3日将康西哥目标价由68美元大幅上调至79美元，维持跑赢大盘评级；此前巴克莱亦将目标价从75美元上调至80美元。投行密集调高估值源于公司Q2业绩大幅超预期——调整后EPS达2.51美元，远超市场预期的1.08美元；营收535.79亿美元，超预期476.17亿美元。公司同步将全年调整后EPS指引上调至高于4.80美元，显著高于市场预估的3.51美元。不过，RBC提示Medicaid利润率或至下半年才有实质性修复，会员人数预期亦有所下调。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.